Gibson Dunn & Crutcher advised Wrexham AFC owners Ryan Reynolds and Rob McElhenney on the transaction. Wrexham AFC owners Ryan Reynolds and Rob McElhenney announced the...
You must be a Standard 1 Year member to access this content.
Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...
You must be a Standard 1 Year member to access this content.
Cravath, Swaine & Moore LLP is advising Vista Outdoor on the transaction, and Gibson, Dunn & Crutcher is advising the independent directors of Vista Outdoor. Vista...
You must be a Standard 1 Year member to access this content.
Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel to Trimble, Gibson, Dunn & Crutcher LLP, Fenwick & West LLP and Fish &...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher is advising the investment banks on the deal. Waste Management, Inc., a Delaware corporation (NYSE: WM) (“WM”), announced that it has commenced...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Alcon Inc. on the deal, and Morrison & Foerster advised OcuMension Therapeutics. OcuMension Therapeutics (“OcuMension”), a Hong Kong-listed, China-based ophthalmic pharmaceutical...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Rose advised Sixth Street. Arrowhead...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Wafra Inc. on the transaction, and Kirkland & Ellis advised Citation Capital. Wafra Inc. (“Wafra”) announced a strategic investment in Citation...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher advised Esperion Therapeutics, Inc. on the deal. Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced that it has entered into a Royalty Purchase Agreement...
You must be a Standard 1 Year member to access this content.
Skadden advised Eyebiotech Limited, while Gibson, Dunn & Crutcher advised Merck the deal. Merck, known as MSD outside of the United States and Canada, and Eyebiotech...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher is advising Kimberly-Clark Corporation on the transaction. Ansell announced it has entered into a binding agreement to acquire 100% of the assets...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised LyondellBasell on the offering. LyondellBasell (NYSE: LYB) announced that LYB International Finance III, LLC, its wholly-owned subsidiary, priced a public offering of $750,000,000...
You must be a Standard 1 Year member to access this content.
